Loading…
Jasper Therapeutics, Inc. is projected to rise to $0.9875 by 2027, a +9% move from its current price of $0.9024. JSPR is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $0.8636 | $0.903 | $0.9441 | +0.06% |
| May 30 | $0.8484 | $0.9036 | $0.9623 | +0.13% |
| May 31 | $0.837 | $0.9041 | $0.9767 | +0.19% |
| Jun 1 | $0.8276 | $0.9047 | $0.9891 | +0.26% |
| Jun 2 | $0.8194 | $0.9053 | $1.00 | +0.32% |
| Jun 3 | $0.8122 | $0.9059 | $1.01 | +0.39% |
| Jun 4 | $0.8057 | $0.9065 | $1.02 | +0.45% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.8057 | $0.9065 | $1.02 | +0.45% |
| Week 2 | $0.7707 | $0.9105 | $1.08 | +0.90% |
| Week 3 | $0.7457 | $0.9146 | $1.12 | +1.36% |
| Week 4 | $0.7258 | $0.9188 | $1.16 | +1.81% |
| Week 5 | $0.709 | $0.9229 | $1.20 | +2.27% |
| Week 6 | $0.6945 | $0.9271 | $1.24 | +2.73% |
| Week 7 | $0.6817 | $0.9312 | $1.27 | +3.20% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapeutics targeting mast stem cell driven diseases in the United States. Its lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factors from binding to and signaling through the CD117 receptor on mast and stem cells.
The company focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma. Jasper Therapeutics, Inc. was founded in 2018 and is headquartered in Redwood City, California.
Jasper Therapeutics, Inc. (JSPR) is a healthcare stock currently priced at $0.903 with a market cap of $25.28M and a market rank of 4879. The stock trades in the Healthcare category. The current price sits near the lower end of the stock’s 30-day activity range, signaling a modest move as investors assess upcoming catalysts.
A major floor 26.0% below — a decisive break under it would weaken the trend.
The nearest floor, 10.6% below — buyers have tended to step in here.
The nearest ceiling, 17.5% above — a clean break opens room to run.
A major ceiling 81.7% above — clearing it would confirm fresh momentum.
Key JSPR support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of JSPR market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.8926 | Buy | $0.8936 | Buy |
| MA 10 | $0.8817 | Buy | $0.8919 | Buy |
| MA 20 | $0.9081 | Sell | $0.9037 | Sell |
| MA 50 | $0.9422 | Sell | $0.9904 | Sell |
| MA 100 | $1.19 | Sell | $1.25 | Sell |
| MA 200 | $1.72 | Sell | $2.32 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 48.32 | Neutral |
| Stoch RSI (14) | 81.18 | Sell |
| CCI (20) | -11.54 | Neutral |
| Williams %R (14) | -37.50 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | -2.59 | Sell |
| Bollinger %B (20,2) | 0.47 | Neutral |
| Stochastic %K (14) | 62.50 | Neutral |
| TRIX (15) | -0.35 | Sell |
| Awesome (5,34) | -0.03 | Sell |
| Ultimate (7,14,28) | 57.31 | Neutral |
| Momentum (10) | -0.01 | Sell |
| Aroon Osc (25) | -40.00 | Sell |
| Hull MA (9) | 0.92 | Sell |
| ADX (14) | 10.38 | Neutral |
| ATR (14) | 0.03 | Info |
The 30-day sentiment is NEUTRAL with an RSI of 50. The 50-day simple moving average is $0.9551 and the 200-day simple moving average is $1.74, indicating the near-term price is hovering around the mid-point of longer-term trends. A floor is noted at $0.807 and a ceiling at $1.06, giving a defined near-term trading range.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.668 | $0.9024 | $1.19 | 0% | Neutral | |
| $0.7352 | $0.9875 | $1.43 | +9% | Neutral | |
| $0.6333 | $0.8922 | $1.36 | -1% | Neutral | |
| $0.5563 | $0.8162 | $1.30 | -10% | Neutral | |
| $0.5381 | $0.819 | $1.35 | -9% | Neutral | |
| $0.55 | $0.8661 | $1.47 | -4% | Neutral | |
| $0.6499 | $1.06 | $1.84 | +17% | Neutral | |
| $0.6862 | $1.15 | $2.06 | +28% | Bullish | |
| $0.7097 | $1.23 | $2.24 | +36% | Bullish | |
| $0.6912 | $1.23 | $2.29 | +36% | Bullish | |
| $0.8746 | $1.78 | $3.62 | +98% | Bullish | |
| $0.993 | $2.21 | $5.05 | +145% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $0.668 | $0.9024 | $1.07 | +0.00% |
| June 2026 | $0.779 | $0.9276 | $1.14 | +2.79% |
| July 2026 | $0.7924 | $0.9568 | $1.20 | +3.15% |
| August 2026 | $0.7516 | $0.9175 | $1.17 | -4.11% |
| September 2026 | $0.7187 | $0.8854 | $1.15 | -3.50% |
| October 2026 | $0.7363 | $0.9147 | $1.20 | +3.31% |
| November 2026 | $0.7378 | $0.9234 | $1.22 | +0.95% |
| December 2026 | $0.707 | $0.8912 | $1.19 | -3.49% |
Click any year to see its month-by-month JSPR forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The JSPR price prediction for 2026 points to an average of $0.9024 (low $0.668, high $1.19) — a potential gain of 0% on today's $0.9024. Price action looks broadly range-bound.
In 2027, JSPR is projected to trade between $0.7352 and $1.43, averaging $0.9875 — a potential gain of +9% from today's $0.9024. That is up +9% on the projected 2026 average. A consolidation phase looks the most probable path here.
Jasper Therapeutics, Inc.'s 2028 outlook centres on $0.8922, within a $0.6333 to $1.36 range. That is -10% versus the projected 2027 average. That marks a -1% change versus current levels. Price action looks broadly range-bound.
By 2029, JSPR could reach as high as $1.30, with a base case around $0.8162 and support toward $0.5563 — roughly -10% from $0.9024. A consolidation phase looks the most probable path here.
Expect JSPR to range from $0.5381 to $1.35 through 2030. The $0.819 average target implies a -9% move from current prices. That is up 0% on the projected 2029 average. Price action looks broadly range-bound.
The JSPR price prediction for 2031 points to an average of $0.8661 (low $0.55, high $1.47) — a potential decline of -4% on today's $0.9024. A consolidation phase looks the most probable path here.
In 2032, JSPR is projected to trade between $0.6499 and $1.84, averaging $1.06 — a potential gain of +17% from today's $0.9024. That is up +22% on the projected 2031 average. Price action looks broadly range-bound.
Jasper Therapeutics, Inc.'s 2033 outlook centres on $1.15, within a $0.6862 to $2.06 range. That is up +9% on the projected 2032 average. That marks a +28% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, JSPR could reach as high as $2.24, with a base case around $1.23 and support toward $0.7097 — roughly +36% from $0.9024. Momentum favours further upside here.
Expect JSPR to range from $0.6912 to $2.29 through 2035. The $1.23 average target implies a +36% move from current prices. That is up 0% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The JSPR price prediction for 2040 points to an average of $1.78 (low $0.8746, high $3.62) — a potential gain of +98% on today's $0.9024. Momentum favours further upside here.
In 2050, JSPR is projected to trade between $0.993 and $5.05, averaging $2.21 — a potential gain of +145% from today's $0.9024. That is up +24% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in JSPR today (≈ 1,108.156028 JSPR) could be worth
$2,445.38
+$1,445.38 (+145%) by 2050 · US Dollar
Based on the average projected JSPR price of $2.21 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in JSPRwould be worth at today's price.
$1,000 invested in JSPR on May 27, 2025 (≈ 209.643607 JSPR) would be worth
$189.18
-$810.82 (-81.1%) today · 0.19× · US Dollar
Based on a JSPR entry price of $4.77 vs. today's $0.9024.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.872 | $1,034.86 | +3.5% |
| 1 month ago | $0.93 | $970.32 | -3.0% |
| 3 months ago | $1.37 | $658.69 | -34.1% |
| 6 months ago | $1.84 | $490.43 | -51.0% |
| 1 year ago | $4.77 | $189.18 | -81.1% |
| All time (5.0y) ago | $99.1 | $9.11 | -99.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our JSPR forecast.
Our base-case forecast reaches $1.80 around 2050.
Implied market cap at $1.80: $50.39M
The multi-year forecast shows a path from flat-to-moderate near-term levels toward stronger growth in the longer term. In 2030 the average forecast price is $0.8201 with a -9.2 ROI, and in 2040 the average forecast price rises to $1.77 with a 95.8 ROI. By 2050 the average forecast price reaches $2.16 with a 139 ROI.
The forecast also highlights significant upside beginning in 2033 (avg $1.16; ROI 28.3) followed by continued gains through 2034 (avg $1.22; ROI 34.9) and 2035 (avg $1.22; ROI 35). These figures are estimates and not guarantees, and they should be considered with awareness of inherent uncertainty and possible downside.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $0.8201, with a minimum of $0.5279 and a maximum of $1.38, and a forecast ROI of -9.2.
The forecast presents a mix of neutral and bullish periods. Near term includes years with neutral expectations and some negative ROIs (e.g., 2029 ROI -11.5 and 2030 ROI -9.2), while years such as 2033 (ROI 28.3), 2040 (ROI 95.8), and 2050 (ROI 139) project stronger upside.
Yes. The forecast shows the average price hitting $1.00 in 2027, and remaining above $1 in years such as 2032 ($1.04), 2033 ($1.16), 2034 ($1.22), and 2035 ($1.22). The later horizon also projects higher averages: 2040 $1.77 and 2050 $2.16.
The max forecast price by 2050 is $4.96.
Rank: 4879; Market cap: $25.28M.
Jasper Therapeutics, Inc. Community Discussion
0Share your Jasper Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.